Generate Biomedicines (GENB) Stock Price, News & Analysis

Company Overview

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and machine learning to discover and design protein-based medicines. Its technology is intended to model relationships among protein sequences, structures and biological functions, helping researchers create therapeutic proteins with desired characteristics.

The company’s research activities are focused on developing novel biologic medicines for areas of significant unmet medical need, including oncology, immunology, infectious diseases and rare diseases. Its platform is designed to support the discovery and optimization of potential drug candidates, with programs directed toward proteins such as antibodies and other engineered therapeutics.

Generate Biomedicines was founded as a Flagship Pioneering company and is based in the United States. The company combines computational biology, artificial intelligence and laboratory experimentation in an effort to accelerate the development of protein therapeutics for patients worldwide.

Key Stats

• Today's Range: $16.53 to $17.30
• 50-Day Range: $13.08 to $20.38
• 52-Week Range: $11.00 to $22.67
• Volume: 427,984 shs
• Average Volume: 809,727 shs
• Market Capitalization: $2.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.40
• Consensus Rating: Moderate Buy

Generate Biomedicines Stock Analysis - MarketRank™

Generate Biomedicines scored higher than 61% of companies evaluated by MarketBeat, and ranked 334th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Generate Biomedicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Generate Biomedicines has a consensus price target of $26.40, representing about 59.1% upside from its current price of $16.59.

Amount of Analyst Coverage

Generate Biomedicines has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Generate Biomedicines are expected to grow in the coming year, from ($2.29) to ($2.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Generate Biomedicines is -10.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Generate Biomedicines is -10.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.81% of the float of Generate Biomedicines has been sold short.

Short Interest Ratio / Days to Cover

Generate Biomedicines has a short interest ratio ("days to cover") of 3.74, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Generate Biomedicines has recently increased by 2.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Generate Biomedicines does not currently pay a dividend.

Dividend Growth

Generate Biomedicines does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.29

News Sentiment

Generate Biomedicines has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Generate Biomedicines this week, compared to 3 articles on an average week.

Search Interest

8 people have searched for GENB on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

7 people have added Generate Biomedicines to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Generate Biomedicines insiders have not sold or bought any company stock.

Percentage Held by Institutions

Generate Biomedicines has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/18/2026
• Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GENB
• CIK: 2100782
• Web: www.generatebiomedicines.com
• Phone: (888) 469-0055
• Fax: N/A
• Employees: 312
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Generate Biomedicines: $26.40
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: +58.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.30
• Quick Ratio: 8.30

Sales & Book Value

• Annual Sales: $26.48 million
• Price / Sales: 80.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 128,352,000
• Free Float: N/A
• Market Cap: $2.13 billion
• Optionable: N/A
• Beta: N/A